AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00985660
Drug: Sular® Extended Release Tablets, 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 30 mg Tablet under fasting conditions
Trial: NCT02155088
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation beginning at 250 mg/day
Trial: NCT04032197
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Trial: NCT01874626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT01874626
Drug: SST-0225 Topical Ibuprofen Cream
RxNorm normalized name: ibuprofen Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST-0225 Topical Ibuprofen Cream
Trial: NCT00612651
Drug: Temodar and SCH 66336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
Trial: NCT02429102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02146209
Drug: Flagyl 125 mg/5 ml oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 500 mg (20 ml suspension)
Trial: NCT00790556
Drug: MK8245
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
Trial: NCT00790556
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
Trial: NCT01481402
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liothyronine 40 microgram per day
Trial: NCT01481402
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
Trial: NCT00348335
Drug: Ocular lubricant
RxNorm normalized name: ocular lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00165217
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02455453
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00368459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical appearing placebo
Trial: NCT01062009
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 200 mcg/ml in Normal Saline
Trial: NCT03610334
Drug: IFB-088 (2.5-60.0mg) oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Trial: NCT03610334
Drug: Placebo (2.5-60.mg) oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Trial: NCT03610334
Drug: IFB-088 (15.0-50.0mg) oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Trial: NCT03610334
Drug: Placebo oral (15.0-50.0mg) capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Trial: NCT02020889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as 0.9% sodium chloride
Trial: NCT00809094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00397189
Drug: placebo circadin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo circadin tablets
Trial: NCT00893074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo dronabinol administered 3x/day for 5 days
Trial: NCT04470479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00287729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Trial: NCT01515202
Drug: Placebo matching with BMS-823778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, 14 days
Trial: NCT00966641
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single orally administered dose of 500 mg naproxen
Trial: NCT00966641
Drug: PL 3100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single orally administered dose of PL 3100 (500 mg naproxen)
Trial: NCT00170950
Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
Trial: NCT00170950
Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
Trial: NCT02334345
Drug: Evoskin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Trial: NCT02334345
Drug: Trixiera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Trial: NCT00170950
Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Trial: NCT01939223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
Trial: NCT01860716
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
Trial: NCT01860716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230971
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Trial: NCT02098395
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Trial: NCT01204918
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02382809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash, twice daily
Trial: NCT02895191
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the placebo for 7 to 14 days
Trial: NCT01861002
Drug: Intrathecal Methotrexate (IT MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. - 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. - 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg
Trial: NCT02709798
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02709798
Drug: 5% Glucose Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754285
Drug: LF-PB and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00915603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO daily continuously for all 28 days of a cycle
Trial: NCT03188783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
Trial: NCT00226798
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03290391
Drug: Pharmacotherapy for opioid use disorder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
Trial: NCT01136564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules daily
Trial: NCT03134911
Drug: DOAC or VKA
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months - 2 years
Trial: NCT04388176
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 as first treatment
Trial: NCT04388176
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 as second treatment
Trial: NCT04388176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as second treatment
Trial: NCT04388176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as first treatment
Trial: NCT02648464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02799277
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effect of testosterone on moral decision making
Trial: NCT01290575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, Oral, 0.0mg, twice daily, 14 day
Trial: NCT01290575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 0.0mg, once daily, 14 day
Trial: NCT04633772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9%
Trial: NCT02454751
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One time dose of 50mcg of fentanyl administered intranasally
Trial: NCT04956939
Drug: Low dose levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Low frequency is defined as ≤ 3 LD doses a day
Trial: NCT04956939
Drug: High dose levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High frequency dosage is defined as ≥ 5 LD doses per day
Trial: NCT02461056
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
Trial: NCT04135313
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2, bid, per os, days 1-14
Trial: NCT04135313
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Trial: NCT00534417
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
Trial: NCT03538691
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.
Trial: NCT00765817
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice a day
Trial: NCT00263471
Drug: 7-methylxanthine
RxNorm normalized name: METHYLXANTHINES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253888
Drug: TPV - Room condition
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253888
Drug: TPV - Refrigerated conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185456
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metronidazole 500 mg twice a day for 7 days
Trial: NCT03964688
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intravenous during hospitalization, after oral, total 6 weeks
Trial: NCT04823390
Drug: Midazolam-Fentanyl combination
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sedation is given to patients undergoing cataract surgery under local anesthesia
Trial: NCT00092963
Drug: Comparator: placebo / Duration of Treatment: 1 day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03955809
Drug: % 0.9 NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular %0.9 NaCl
Trial: NCT02475772
Drug: Cisplatin and doxorubicin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
Trial: NCT02512172
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02442206
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Trial: NCT02442206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Trial: NCT02421588
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03827798
Drug: LOU064 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o.
Trial: NCT03827798
Drug: Placebo to LOU064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o.
Trial: NCT03827798
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c.
Trial: NCT03827798
Drug: Placebo to VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c.
Trial: NCT00437476
Drug: Nucleoside Reverse Transcriptase Inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs for 26 weeks (A) or 24 weeks (B)
Trial: NCT04304508
Drug: BAY2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, taken orally once a day.
Trial: NCT04733625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication
Trial: NCT02349139
Drug: ASN001: Escalating dose Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen inhibitor
Trial: NCT02579382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally once a week (every 7 days) for 12 doses
Trial: NCT00151476
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg total daily dosing
Trial: NCT03091426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT01137656
Drug: Acetylcholine and Blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
Trial: NCT02706769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication contains blinded placebo
Trial: NCT04027179
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Trial: NCT02797145
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
Trial: NCT04099238
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
Trial: NCT04098796
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
Trial: NCT02634801
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03692715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
Trial: NCT00134966
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02588586
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3BNC117 infusions
Trial: NCT00215644
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Trial: NCT01352273
Drug: MEK162 + RAF265
FDA approved: no
EMA approved: no
PMDA approved: no